Drug
Acyclovir 400 MG
Acyclovir 400 MG is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph not_applicable
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (33.3%)
N/A2 (66.7%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completednot_applicable
Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis
NCT06757907
completednot_applicable
Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject
NCT04988646
completedphase_2
Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies
NCT03159845
Clinical Trials (3)
Showing 3 of 3 trials
NCT06757907Not Applicable
Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis
NCT04988646Not Applicable
Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject
NCT03159845Phase 2
Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3